Trials / Completed
CompletedNCT02713295
A Study to Provide Real-world Evidence on the Treatment Goal Achievement Rate, Adherence to and Utilization Patterns of Adalimumab in Patients With Moderate to Severe Plaque Psoriasis in Greece
A Non-interventional Prospective Cohort Study to Provide Real-world Evidence on the Treatment Goal Achievement Rate, Adherence to and Utilization Patterns of Adalimumab in Patients With Moderate to Severe Plaque Psoriasis in Greece
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 273 (actual)
- Sponsor
- AbbVie · Industry
- Sex
- All
- Age
- 18 Years – 99 Years
- Healthy volunteers
- Not accepted
Summary
This study estimates the treatment goal achievement rate, depicts the implementation of the Progressive Psoriasis Initiative (PPI) recommendations regarding treatment modifications and transitioning, and assesses patient adherence and persistence with adalimumab therapy in the routine clinical practice in Greece.
Conditions
Timeline
- Start date
- 2016-06-16
- Primary completion
- 2019-04-19
- Completion
- 2019-04-19
- First posted
- 2016-03-18
- Last updated
- 2020-04-15
Locations
43 sites across 1 country: Greece
Source: ClinicalTrials.gov record NCT02713295. Inclusion in this directory is not an endorsement.